Scientists have identified phosphatidylserine as the trigger for LC3-associated phagocytosis (LAP), clarifying how this key cellular degradation process is initiated. This discovery opens new avenues for therapies that target LAP in cancer and autoimmune diseases. ow.ly/SuNO50X0hN8

Wishing our FANTASTIC postdoctoral fellows, Harsh Kumar, Christina Daly, Sam Hack, and Rojalin Pradhan, a great Postdoctoral Appreciation Week! Thanks for all you do for the lab and for @stjuderesearch.bsky.social! 🧪

Appreciating these 2 during Postdoc Appreciation Week @stjuderesearch.bsky.social! Esmat @esfa.bsky.social spearheading our GNAI1 studies and Dianne (new!) embarking on her #raredisease research journey with us. 🧬 🧠 🧬

St. Jude, the government of Uzbekistan, WHO and Zamin Foundation are co-hosting a 90-minute side event at UN Headquarters after UNGA to highlight how leadership, collaboration and innovation are improving health outcomes for children worldwide.

A new study shows that combining indisulam with anti-GD2 immunotherapy achieves a complete therapeutic response in preclinical neuroblastoma models, regardless of tumor cell state. This could change the outlook for high-risk patients. ow.ly/yR3i50WY7tK

During National Postdoc Appreciation Week, we celebrate the contributions of our 365 postdoctoral researchers, their dedication to advancing our mission and how St. Jude is supporting postdocs with resources, mentorship and career development opportunities.

Listen to my new lecture "Developmental mutagenesis: A unified theory of why young people develop cancer" as part of @stjude.bsky.social @stjuderesearch.bsky.social Science of Childhood Lecture Series on September 18, 2025: www.linkedin.com/events/73719...

New research shows certain mitochondrial DNA mutations occur before cancer develops and are not always random. These mutations can contribute to therapy resistance in pediatric leukemia. ow.ly/V39G50WViNa

St. Jude is hosting the Virtual Research Career, Education & Training Fair on Thursday, September 25, from 10 AM – 3 PM CT. This free event is geared towards students, trainees and professionals in biomedical research and research information technology.

The SCDSTEMM clinical trial at St. Jude hopes to advance sickle cell disease research by improving stem cell collection methods. The study aims to decrease the time and resources needed for treatment, thus making gene therapy more accessible.

The 2025 Scientific Report highlights advances in pediatric leukemia research, including improved survival for acute lymphoblastic leukemia (ALL) and new strategies for rare and treatment-resistant subtypes. ow.ly/exOA50WPVZV

During Spinal Muscular Atrophy (SMA) Awareness Month, St. Jude spotlights the work of Sam Hughes, operations manager for the Center for Experimental Neurotherapeutics. Hughes played a key role in a clinical trial exploring prenatal treatment for SMA.

The 2025 St. Jude Scientific Report highlights breakthroughs in pediatric medicine: microscopy advancing biology, precision genomics in leukemia care, predictive medicine for survivors and innovations in immunotherapy. Read more: ow.ly/tmQQ50WMRiB

Ependymoma, the third most common childhood brain tumor, has seen little therapeutic progress in 30+ years. New findings reveal how the ZFTA–RELA fusion protein drives tumor formation via condensates. ow.ly/fg4r50WMPZJ

The Career Advancement Program (CAP) fellowship at St. Jude helps early career scientists like Cameron Ogg, PhD, explore career paths outside of the lab. CAP provides immersive, hands-on training and mentorship to equip postdocs for diverse roles in academia, industry and beyond.

New research demonstrates the protein midkine’s protective role against Alzheimer’s disease, inhibiting the formation of amyloid beta assemblies which are central to disease progression. ow.ly/uX3y50WJzgw

Findings from an international clinical trial co-led by Richard Finkel, MD, reveal risdiplam, a drug used to treat spinal muscular atrophy (SMA), is safe and effective in newborns. ow.ly/PHwo50WFC12

Scientists at St. Jude created an AI-informed computational method to rapidly screen large numbers of theoretical bi-specific tandem CAR designs, improving the ability to target and treat challenging tumors. ow.ly/TfJh50WFlkJ

We are excited to kick off this season of SOCC with a milestone: our 150th lecture. Join us every Thursday, from 8/14 to 11/20, at 12 PM CT / 1 PM ET for an engaging and interactive 15-week virtual lecture series.

Ewing sarcoma is the second most common bone cancer in children. St. Jude researchers are targeting one of its critical vulnerabilities: impaired DNA repair. Learn more about targeting DNA repair with PARP inhibitors.

Shape the future of childhood cancer survivorship with the 2026 CCSS Ann C. Mertens Career Development Award. This opportunity provides early-career investigators with the tools, resources and mentorship to advance survivorship research and improve outcomes.

Rare diseases often defy diagnosis and treatment, especially metabolic disorders impacting the nervous system. Andrea Gropman, MD, is leading efforts at St. Jude to uncover the biology behind these conditions and develop patient-centered research approaches. ow.ly/hhsu50WAGk8

Investigators have uncovered the full activation mechanism of sweet taste receptors, proteins that detect sugar and sweeteners. Their findings could guide the design of better sugar substitutes. ow.ly/X3Sl50Wzuts

In 2019, St. Jude developed a life-saving gene therapy for infants with SCID-X1 (“bubble boy disease”), enabling them to form immune systems for the first time. Today, researchers reveal a specialized immune cell type called virtual memory T cells. ow.ly/UgFN50WybY5

Ninad Oak, PhD, Lead Bioinformatics Research Scientist at St. Jude, uses sketchnoting to make science accessible. By visually summarizing research talks and papers, he simplifies complex ideas—a practice he now incorporates into mentoring students. @ninadoak.bsky.social

St. Jude will be the first U.S. institution to introduce 3D pharmaceutical compounding for direct pediatric care, transforming medication delivery for children. Learn how this innovation is reshaping pediatric health care: ow.ly/h6sz50WwPeN

H5N1 avian influenza found in dairy cattle retains bird-infecting features, posing a low risk of sparking a human pandemic, according to new research from St. Jude scientists. ow.ly/T1fF50WwmGA

Joshua Burns, PhD, is expanding the Human Performance Lab to include rare neurological disorders with a new Gait and Mobility Lab that captures precision movement data using cutting-edge technology.

Understanding the genetic causes of pediatric epilepsy is essential for improving diagnosis and treatment. @hcmefford.bsky.social, MD, PhD, and her team are leveraging advanced sequencing technologies and patient-derived models to uncover the genetic roots of epilepsy.

Hearing loss is a significant side effect of childhood cancer treatments such as platinum-based chemotherapy and radiation. A study led by Johnnie Bass, AuD, PhD, found that 61% of survivors qualify for cochlear implant evaluation under expanded criteria. ow.ly/fSuX50WqaGx

Attend the 2025 Bringing Chemistry to Medicine Symposium to learn from leading experts in transcription, chromatin regulation, computational biology and chemical biology. Registration is free and available both in-person and virtually.

Janeala Morsby, PhD, is contributing to research on pediatric osteosarcoma at St. Jude, focusing on genomic targets and combination therapies to improve outcomes for children with this rare cancer.

Through the Pediatric Translational Neuroscience Initiative, St. Jude is uniquely positioned to advance research and treatment for ataxias, rare neurodegenerative disorders, such as Friedreich’s Ataxia (FA) and Ataxia-Telangiectasia (A-T).

St. Jude and @IAEAorg partner to address global disparities in childhood cancer care. The initiative will expand access to pediatric radiotherapy in low- and middle-income countries, strengthen health systems and improve survival rates and quality of life. ow.ly/8Ueq50WkOnb

Renato Umeton, PhD, is driving the use of AI and data science to accelerate discoveries at St. Jude. His work bridges research, clinical care and operations to advance pediatric medicine. Discover his vision for AI’s role in biomedical breakthroughs. ow.ly/5maw50WkIk9

New research reconciles two competing models of transcription organization: phase-separated droplets versus small, soluble protein complexes. Findings reveal these mechanisms are intertwined, offering nuance and caution for interpreting transcription. ow.ly/3OTG50WkxiM

As Cancer Immunotherapy Month comes to a close, we reflect on the discovery-based research that is advancing how the immune system can be harnessed to target and destroy cancer cells.

New research shows gene therapy improves brain blood flow in sickle cell disease patients, reducing stroke risk. Findings suggest patients historically excluded from trials should now be considered. ow.ly/TWOm50WhMH5

St. Jude researchers, along with the University Health Network, reveal that treatment outcomes in pediatric B-ALL are impacted by the stage at which B cells become leukemic. The findings could improve risk stratification and therapy design. ow.ly/fsp150WhsMT

Water molecules are critical to protein structure and function but are often overlooked in drug discovery due to unreliable data. A new tool, ColdBrew, predicts water molecule presence in protein structures, even at higher temperatures, offering insights into drug-binding sites. ow.ly/qrW850WhsIG

Genomic instability drives neurological disease but is also a path to new treatments. At St. Jude, Peter McKinnon, PhD, is uncovering how instability in DNA repair leads to neurodegeneration, apoptosis and even cancer. ow.ly/mHOV50WgKhj

Investigators at St. Jude, CHOP, Dana-Farber, and COG reveal that the same gene mutations in T-cell acute lymphoblastic leukemia had different prognostic impacts depending on genetic ancestry. ow.ly/EfRZ50Wgsvt

Understanding proteins is essential to understanding disease. The St. Jude Protein Production Facility (PPF) creates custom, high-purity proteins for cancer, vaccine and antiviral research, saving time and money while advancing discoveries. ow.ly/bYWg50WeUCN

Survivors of childhood cancer face a 15x higher risk of developing cardiomyopathy. A new study by St. Jude investigators reveals that genetic trends differ from survivors of adult cancer, offering new insights for screening and prevention. ow.ly/Rmv150WcZzp

St. Jude researchers are addressing communication gaps in sickle cell disease care through the GENETX and BINFORMED clinical trials, which use patient interviews to uncover fears, priorities and hopes surrounding gene therapy.

New findings reveal how NUP98 protein fusions drive childhood acute myeloid leukemia and identify a promising combination therapy that significantly improves survival in treatment-resistant models. ow.ly/TsLS50WcjtK

A deeper understanding of how cells organize themselves is changing the way we think about neurological diseases. At St. Jude, researchers are studying biomolecular condensates—droplets that organize proteins, RNA and DNA—to uncover new treatment strategies. ow.ly/tzpp50WbzjK

St. Jude is hosting its annual Bringing Chemistry to Medicine Symposium October 2-3, 2025, in Memphis, TN. In collaboration with @cellpress.bsky.social, the event features global experts sharing cutting-edge advancements at the intersection of chemical and biomedical sciences.

St. Jude researchers and international collaborators developed a more affordable and accessible technique of single-cell RNA analysis that combines microscopy with RNA detection. ow.ly/Er0i50WaQnv

Research by St. Jude Children’s Research Hospital and University College London reports sustained safety and efficacy of gene therapy for hemophilia B 13 years post treatment, the longest follow-up study of its kind. ow.ly/g3lK50W8me4